FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management
Posted on: Wednesday, 28 May 2008, 15:00 CDT
WASHINGTON, May 28 /PRNewswire-USNewswire/ -- Now that the Food and Drug Administration (FDA) has new authority to improve the safe use of pharmaceuticals, drug manufacturers can be required to develop comprehensive risk assessment evaluations and restrict their marketing on existing pharmaceuticals.
To help pharmaceutical companies, consultants and other drug industry stakeholders prepare and comply with the new rules on risk evaluation and mitigation strategy (REMS) mandated under the Food and Drug Administrations Act Amendments of 2007, FDLI has issued the most complete handbook on risk evaluation and management published to date: Pharmaceutical Risk Management: Practical Applications.
This comprehensive, 300-page book, which includes a foreword by Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research at FDA, provides practical guidance to enable drug companies to effectively negotiate the REMS pre- and post-marketing surveillance maze, including:
-- What actions to take to determine if the benefits of a drug outweigh its risks; and -- What to do if FDA decides new safety information requires companies to make changes in the marketing of existing drugs. The nuts-and-bolts book also includes instructive chapters on: -- The environmental and historical context for risk management; -- Proven strategies for designing and measuring REMS effectiveness; -- Practical examples and case studies of successful risk management strategies; and -- Crisis management considerations.
The book also contains invaluable appendices, including FDA's guidance for industry on pre-marketing risk assessment.
"Knowing how to design, execute and evaluate a risk management and communications program can spell the difference between drug approval and approval delay," says co-editor Wayne L. Pines, President, Regulatory Services and Healthcare, APCO Worldwide, and former Associate Commissioner at FDA. The other two editors of the book are Jeffrey E. Fetterman, president and CEO of ParagonRx, a healthcare consulting firm, and Gary H. Slatko, M.D., the firm's Chief Medical Officer.
For more information on the book, Pharmaceutical Risk Management: Practical Applications, visit http://www.fdli.org/ or call (202) 371-1420.
Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field.
Food and Drug Law Institute
CONTACT: Michael Levin-Epstein, Editor-in-Chief of the Food and Drug LawInstitute, +1-202-222-0897, mdl@fdli.org
Web Site: http://www.fdli.org/
Source: PRNewswire-USNewswire
Related Articles
- CCID Consulting: Review and Forecast on the Development of Corporate Risk Management Systems in China
- Xstrata Copper Chooses Brady for Global Risk Management
- New Updated Edition of 'Risk Management, and Safety Issues for Medical Practice' Now Available
- Risk Management and Trading Seminar Using Market Profile(TM) Hosted By Intelligence Press
- The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
- Almost All New Drug Approvals Receive FDA Requests for Post-Marketing Studies
- Shire Plc - Statement Regarding the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee Meeting
- Drug Makers Face Fresh Curbs on Misleading Marketing
- AIM Software Establishes Subsidiary in the U.S.; Reference Data Management and Risk Management Solutions for U.S. Clients
 |
 |
User Comments (0)
RSS Feeds